[{"orgOrder":0,"company":"EpilepsyGTx","sponsor":"UCL Technology Fund","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Financing","leadProduct":"EPY201","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"EpilepsyGTx","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"","sponsorNew":"EpilepsyGTx \/ UCL Technology Fund","highestDevelopmentStatusID":"4","companyTruncated":"EpilepsyGTx \/ UCL Technology Fund"}]

Find Clinical Drug Pipeline Developments & Deals by EpilepsyGTx

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Compamed
                          Not Confirmed
                          Compamed
                          Not Confirmed

                          Details : The funds raised will be used to complete the preclinical studies for EpilepsyGTx’ lead gene therapy program EPY201, for the treatment of focal refractory epilepsy.

                          Brand Name : EPY201

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          June 24, 2024

                          Lead Product(s) : EPY201

                          Therapeutic Area : Neurology

                          Highest Development Status : Preclinical

                          Sponsor : UCL Technology Fund

                          Deal Size : $10.0 million

                          Deal Type : Financing

                          blank